A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women

Sarcopenia Clinical Trial

Official title:

A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00986596
• Other study ID #: 2450
• Secondary ID: 7528
• Status: Completed
• Phase: N/A
• First received: September 29, 2009
• Last updated: January 6, 2012
• Start date: October 2006
• Est. completion date: February 2011

Study information

• Verified date: January 2012
• Source: Tufts University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to investigate the effect of vitamin D on muscle tissue and physical performance.

Description:

The investigators have recently observed that among healthy women age 65 and older who participated in a placebo-controlled vitamin D and calcium intervention trial, those treated with supplements had a lower risk of falling than those in the placebo group. Vitamin D receptors (VDRs) are present in muscle tissue and are thought to mediate the favorable effects of vitamin D on muscle performance. Vitamin D insufficiency is common particularly in the elderly and supplementation with a relatively high dose of vitamin D may be a useful approach for improving muscle performance and potentially lowering the risk of falling in sedentary older women and other high-risk populations.

The investigators will aim to study women, age 65 and older, with 25(OH)D levels below 60 nmol/l in a double-blind, 4-month randomized controlled pilot study. Eligible subjects will be randomized to treatment with 4000 IU per day of vitamin D3 or placebo. Blood and 24 hour urine will be measured at the beginning and end of the study as outlined in the intervention and measurement schedule below. In addition, a safety random spot urine will be analyzed for calcium and creatinine on day 30. Muscle performance measures will be measured and muscle biopsies will be performed at the beginning and end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Age 65 and older

• 25 (OH)D levels >22.5 nmol/l or <60 nmol/l

• Women must have a composite physical performance score of = 9 out of a possible score of 12.

• Subjects must agree not to change their usual level of physical activity or change the amount of calcium and vitamin D supplement they use for the duration of the study.

• If they are taking calcium supplements, they must agree to take the supplement any time after lunch.

Exclusion Criteria:

• General:

1. Total calcium intake >1000mg daily on the prescreening questionnaire.

2. More than 400 IU daily of supplemental vitamin D on the prescreening questionnaire.

3. A screening 25(OH)D level > 60 nmol/ L.

4. Screening 24-hour urine calcium > 275 mg.

5. An abnormal serum calcium.

6. Travel to latitude <35 degrees N within 2 months of the time of enrollment; plans to travel to latitude <35 degrees N during the 4-month study, with the likelihood of tanning (e.g. appreciable sun exposure without sun screen).

7. Greater than 2 drinks of alcohol a day.

• Medications:

1. Bone active drugs such as bisphosphonates, estrogen, calcitonin, teriparatide

2. Diuretics

3. Oral glucocorticoids in the last month

4. Phosphates in the last week

5. Lithium

6. Cod liver oil

7. Total parenteral nutrition

8. Calcium containing antacids

9. Coumadin or other prescribed anticoagulants

• Diseases:

1. Active thyroid disease - unstable levothyroxine dose

2. Parathyroid disease

3. Sarcoidosis

4. Fracture of the foot, leg, or hip in the last year

5. Renal stone < 5 years

6. Alkaline phosphatase > 10% above the upper limit of normal

7. Pancreatitis

8. Active malignancy (other than basal cell cancer of the skin) or cancer therapy in the last year

9. Uncontrolled arrhythmia in last year

10. Malabsorption

11. Use of a walker or wheelchair (3-post cane okay)

12. Nasal oxygen use

13. Must have a basic mobility level of walking 4 meters

14. Hemiplegia

15. Tuberculosis

16. Type 1 Diabetes mellitus or unstable type 2 diabetes mellitus (fasting blood glucose >130 mg/dL)

17. Other abnormality in screening labs, at the discretion of the study physician

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Falls
• Sarcopenia

Intervention

Dietary Supplement:
• vitamin D3
4000 IU once daily by mouth for 4 months
• Placebo
microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)

Locations

Country	Name	City	State
United States	Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Tufts University	Boston Medical Center, National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Define and compare changes in size and number of type II muscle fibers in response to 4 months of treatment with 4000 IU of vitamin D3 per day or placebo in older women with low-normal 25(OH)D levels.		4 months	No
Secondary	Define and compare vitamin D signaling in muscle biopsy specimens taken before and after the treatment.		4 months	No
Secondary	Define and compare changes in clinical measures of muscle performance before and after treatment		4 months	No
Secondary	Define and compare levels of bone turnover before and after treatment		4 months	No